Table 3. Correlations between PPP3CB expression and clinicopathological characteristics.

	PPP3CB low expression (n=23)	PPP3CB high expression (n=32)	P-value
Age
<60	10 (43.5%)	12 (37.5%)	0.655
≥60	13 (56.5%)	20 (62.5%)
Sex
Male	15 (65.2%)	22 (68.8%)	0.783
Female	8 (34.8%)	10 (31.3%)
Primary tumor location
Head and neck	14 (60.9%)	18 (56.3%)	0.732
Body and tail	9 (39.1%)	14 (43.8%)
Nuclear grade
I-II	16 (69.6%)	29 (90.6%)	0.075
III	7 (30.4%)	3 (9.4%)
Vascular invasion
No	13 (56.5%)	15 (46.9%)	0.480
Yes	10 (43.5%)	17 (53.1%)
T stage
1-2	23 (100.0%)	24 (75.0%)	0.015
3	0 (0%)	8 (25.0%)
N stage
0	9 (39.1%)	24 (75.0%)	0.007
1	14 (60.9%)	8 (25.0%)
Jaundice
No	17 (73.9%)	25 (78.1%)	0.717
Yes	6 (26.1%)	7 (21.9%)
Abdominal pain
No	10 (43.5%)	12 (37.5%)	0.655
Yes	13 (56.5%)	20 (62.5%)